Day: October 1, 2021

Vancouver, British Columbia, Oct. 01, 2021 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) is pleased to announce that its US-based OTC Markets listing under the symbol “LRDJF” has received confirmation from the Depository Trust Company (“DTC”) that its common shares are now eligible for electronic clearing and settlement through DTC in the United States. St. James Gold Corp.’s CEO, George Drazenovic, welcomed this development. “Today’s news is an important milestone towards broadening our market presence across the United States. DTC eligibility allows current and prospective shareholders of St. James Gold a reliable, cost-efficient, and timely method for the clearing and settlement of our common shares, and positions US investors to participate in our Company’s exciting growth.” The...

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (the “Company” or “Better Choice”), a pet health and wellness company, today announced that it has appointed two new members to its Board of Directors, Lionel Conacher and Arlene Dickinson. They will replace current serving directors, Lori Taylor and Jeff Davis, effective September 28, 2021. Lionel Conacher joins Better Choice with over thirty years of financial experience, spanning senior positions in public companies in both Canada and the US, investment banking, private equity and venture capital. Mr. Conacher currently serves as Chairman of DXL Group (NASDAQ: DXLG), where he has successfully guided the retail chain through the COVID-19 pandemic. In 2018, Mr. Conacher co-founded a San Francisco based venture capital fund, Next Ventures, after serving...

WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021. Details of Replimune’s poster presentations: Abstract Title: A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumorsAbstract Number: 507Session Date and Time: November 12-14, 2021 from 7:00 AM ET- 5:00 PM ETLocation: Hall E Abstract Title: ARTACUS: An open-label, multicenter, phase 1b/2 study of RP1 in solid organ transplant recipients with advanced cutaneous...

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI:...

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held November 10 – 14, 2021 in Washington, DC, and virtually. Details of the poster presentation are as follows: Title: ATYR2810, an anti-NRP2 monoclonal antibody, targets tumor associated macrophagesAuthors: Samantha Tyler, Michaela Ferrer, Erik Escobedo, Kaitlyn Rauch, Sofia Klopp-Savino, Justin Rahman, Zhiwen Xu, Esther Chong, Suzanne Paz, Leslie Nangle. aTyr Pharma, San Diego, CA.Abstract Number: 699Date and Time: November 12 – 14, 2021 from 7:00AM – 5:00PM ET About ATYR2810 aTyr...

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abstracts highlighting the company’s Aryl Hydrocarbon Receptor (AHR) antagonist program, with novel inhibitor IK-175, will be presented at the SITC 2021 Annual Meeting. IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment to increase both innate and adaptive immunity and is currently being studied in a Phase 1 clinical trial. Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) is being held in-person and virtually November 10-14, 2021. Abstract details can be found below.          Aryl Hydrocarbon Receptor (AHR) Antagonist Program Title: A Phase 1a/b Study...

MAINZ, Germany, October 1, 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical and preclinical data will be presented in six posters and one presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 – 14, 2021. The presentations will include new data from multiple programs across various drug classes along with first-in-human data for three programs. This is the largest data collection the company will present at a scientific meeting, showcasing BioNTech’s diversified oncology pipeline. “The data we will be presenting at SITC 2021 is indicative of our continued pursuit of...

Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development programs Update also highlights novel methods for scaling the expansion of engineered NK cells to potentially supply a life cycle’s worth of commercial product from a single donorSOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021. The full abstracts are scheduled to be available on the SITC website on November 9, 2021. Presented...